{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.037","value":"70.90"},{"groupId":"OG001","spread":"20.642","value":"72.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"410"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The mean baseline EORTC QLQ-C30 score is presented.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"OG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"OG001","title":"Sunitinib"}],"paramType":"MEAN","populationDescription":"All participants with non-missing questionnaire assessments at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days])","title":"Mean Baseline EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Score on a scale"}